Clinical and Genomic Features of Response and Toxicity to Sotorasib in a Real-World Cohort of Patients With Advanced KRAS G12C -Mutant Non-Small Cell Lung Cancer.
Rohit ThummalapalliEzra BernsteinBenjamin O HerzbergBob T LiAfsheen IqbalIsabel R PreeshagulFernando C SantiniJuliana EngMarc LadanyiSoo-Ryum YangRonglai ShenPiro LitoGregory J RielyJoshua K SabariKathryn C ArbourPublished in: JCO precision oncology (2023)
comutations were associated with resistance and recent anti-PD-(L)1 therapy exposure was associated with toxicity. These observations may help guide use of sotorasib in the clinic and may help inform the next generation of KRAS G12C-targeted clinical trials.